MARKET

CRDF

CRDF

Cardiff Oncology Inc
NASDAQ
1.780
+0.070
+4.09%
Closed 19:30 02/27 EST
OPEN
1.740
PREV CLOSE
1.710
HIGH
1.835
LOW
1.720
VOLUME
165.60K
TURNOVER
0
52 WEEK HIGH
2.790
52 WEEK LOW
0.9400
MARKET CAP
79.53M
P/E (TTM)
-1.9466
1D
5D
1M
3M
1Y
5Y
Myriad Genetics (MYGN) Tops Q4 Earnings and Revenue Estimates
NASDAQ · 9h ago
Weekly Report: what happened at CRDF last week (0219-0223)?
Weekly Report · 1d ago
Radiopharmaceutical market expected to reach ~$14B by 2032
The international market for radiopharmaceuticals is expected to reach $13.67B by 2032. Radiopharma market expected to grow at a compound annual growth rate of 10.2% from 2023. The rising prevalence of cancer and an aging population are among the tailwinds for market growth.
Seeking Alpha · 2d ago
Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 02/20 13:15
Weekly Report: what happened at CRDF last week (0212-0216)?
Weekly Report · 02/19 12:08
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Cogent Biosciences (NASDAQ:COGT) shares rose 45.6% to $7.95 during Wednesday's pre-market session. Lineage Cell Therapeutics (AMEX:LCTX) stock rose 18.62% during the session. Alaunos Therapeutic stock increased by 17.39%. Losers Anitra stock declined by 67.8% and QuidelOrtho stock fell 39.35%.
Benzinga · 02/14 13:05
Weekly Report: what happened at CRDF last week (0205-0209)?
Weekly Report · 02/12 11:55
Strength Seen in Regenxbio (RGNX): Can Its 11.7% Jump Turn into More Strength?
NASDAQ · 02/08 09:50
More
About CRDF
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies across a range of cancers with unmet medical needs. The Company is focused on tumor vulnerabilities with treatment combinations of onvansertib, its selective PLK1 inhibitor, and standard of care (SoC) therapeutics. The Company has five ongoing clinical trials of onvansertib, including two trials (TROV-054 and ONSEMBLE) in second-line treatment in patients with KRAS-mutated Metastatic Colorectal Cancer (mCRC), one trial in second-line treatment in patients with Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC), and two investigator-initiated trials in patients with unresectable locally advanced or metastatic Triple Negative Breast Cancer (TNBC) and relapsed Small Cell Lung Cancer (SCLC). The Company has third-party manufacturers and distributors to supply and distribute onvansertib used in its clinical studies and nonclinical development programs.

Webull offers Cardiff Oncology Inc stock information, including NASDAQ: CRDF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRDF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRDF stock methods without spending real money on the virtual paper trading platform.